

Non-clinical trial and IND approval of high efficiency BCMA CAR-T cell therapy



ONCOLOGY	Preclinical
Product Type	Cell therapies
Indication	Multiple Myeloma
Target	BCMA (B-Cell Maturation Antigen)
MoA(Mechanism of Action)	By recognizing and binding cancer through BCMA-targeting scFv, it activates t cells and causes anticancer effects
Competitiveness	By applying antibodies with fast binding/dissociation rate to the target antigen, the residual time and reaction rate of car-t cells in the body are increased, and humanized antibodies are applied to minimize the immune response
Development Stage	Preclinical
Route of Administration	IV infusion

Any unauthorized distribution or reproduction of this material is strictly prohibited.